{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:28:11Z","timestamp":1791379691600,"version":"4.3.3"},"reference-count":52,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.10.072","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T09:30:10Z","timestamp":1509183010000},"page":"6949-6956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes"],"prefix":"10.1016","volume":"35","author":[{"given":"A.","family":"Landi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ebensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Deschatelets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.J.","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2017.10.072_b0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.vaccine.2017.10.072_b0010","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMp1400986","article-title":"Curing chronic hepatitis C\u2013the arc of a medical triumph","volume":"370","author":"Chung","year":"2014","journal-title":"N Engl J Med"},{"issue":"7496","key":"10.1016\/j.vaccine.2017.10.072_b0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/508295a","article-title":"Hepatitis C drugs not reaching poor","volume":"508","author":"Callaway","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.10.072_b0020","unstructured":"Gozlan Y, et al., Resistance of Hcv to new direct acting antivirals. Harefuah 2015; 154(11): 684\u2013687, 743."},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.072_b0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","article-title":"Hepatitis C reinfection after sustained virological response","volume":"64","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"issue":"6250","key":"10.1016\/j.vaccine.2017.10.072_b0030","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.aad1302","article-title":"MEDICINE. Global control of hepatitis C virus","volume":"349","author":"Cox","year":"2015","journal-title":"Science"},{"issue":"39","key":"10.1016\/j.vaccine.2017.10.072_b0035","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1016\/j.vaccine.2009.06.106","article-title":"Inactivated Polio Vaccine (IPV): a strong candidate vaccine for achieving global polio eradication program","volume":"27","author":"Shahzad","year":"2009","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.vaccine.2017.10.072_b0040","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.072_b0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","article-title":"Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses","volume":"239","author":"Houghton","year":"2011","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.072_b0050","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/655902","article-title":"Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins","volume":"202","author":"Ray","year":"2010","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.072_b0055","doi-asserted-by":"crossref","first-page":"e59776","DOI":"10.1371\/journal.pone.0059776","article-title":"A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans","volume":"8","author":"Law","year":"2013","journal-title":"PLoS One"},{"issue":"12\u201313","key":"10.1016\/j.vaccine.2017.10.072_b0060","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S0264-410X(97)00054-6","article-title":"Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties","volume":"15","author":"Goto","year":"1997","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2017.10.072_b0065","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.vaccine.2004.07.050","article-title":"Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro","volume":"23","author":"Morefield","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.072_b0070","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.181.6.3755","article-title":"Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome","volume":"181","author":"Kool","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.072_b0075","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1084\/jem.20071087","article-title":"Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells","volume":"205","author":"Kool","year":"2008","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.072_b0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2567.2007.02751.x","article-title":"Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection","volume":"124","author":"Agger","year":"2008","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.072_b0085","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11591760-000000000-00000","article-title":"Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach","volume":"25","author":"Garcon","year":"2011","journal-title":"BioDrugs"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.072_b0090","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/erv.09.123","article-title":"Currently approved prophylactic HPV vaccines","volume":"8","author":"Harper","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2017.10.072_b0095","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1073\/pnas.0813390106","article-title":"Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"30","key":"10.1016\/j.vaccine.2017.10.072_b0100","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.0804699105","article-title":"Molecular and cellular signatures of human vaccine adjuvants","volume":"105","author":"Mosca","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.072_b0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/cimm.1998.1283","article-title":"Dendritic cells internalize vaccine adjuvant after intramuscular injection","volume":"186","author":"Dupuis","year":"1998","journal-title":"Cell Immunol"},{"issue":"7370","key":"10.1016\/j.vaccine.2017.10.072_b0110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nature10429","article-title":"STING is a direct innate immune sensor of cyclic di-GMP","volume":"478","author":"Burdette","year":"2011","journal-title":"Nature"},{"issue":"5986","key":"10.1016\/j.vaccine.2017.10.072_b0115","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1189801","article-title":"c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response","volume":"328","author":"Woodward","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.072_b0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbrc.2005.01.093","article-title":"3\u2032,5\u2032-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation","volume":"329","author":"Karaolis","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.072_b0125","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.vaccine.2006.10.033","article-title":"The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties","volume":"25","author":"Ebensen","year":"2007","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2017.10.072_b0130","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1016\/j.vaccine.2011.05.026","article-title":"Bis-(3\u2032,5\u2032)-cyclic dimeric adenosine monophosphate: strong Th1\/Th2\/Th17 promoting mucosal adjuvant","volume":"29","author":"Ebensen","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.072_b0135","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/14760584.2016.1195265","article-title":"Archaeal lipid vaccine adjuvants for induction of cell-mediated immunity","volume":"15","author":"Haq","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.072_b0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0378-5173(99)00331-2","article-title":"In vitro assessment of archaeosome stability for developing oral delivery systems","volume":"194","author":"Patel","year":"2000","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.072_b0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/0738-859991229170","article-title":"Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems","volume":"19","author":"Patel","year":"1999","journal-title":"Crit Rev Biotechnol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.072_b0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1128\/IAI.68.1.54-63.2000","article-title":"Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum","volume":"68","author":"Krishnan","year":"2000","journal-title":"Infect Immun"},{"issue":"17","key":"10.1016\/j.vaccine.2017.10.072_b0155","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.vaccine.2008.02.026","article-title":"Archaeosome adjuvants: immunological capabilities and mechanism(s) of action","volume":"26","author":"Krishnan","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.072_b0160","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01552-16","article-title":"Native folding of a recombinant gpE1\/gpE2 heterodimer vaccine antigen from a precursor protein fused with Fc IgG","volume":"91","author":"Logan","year":"2017","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.072_b0165","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s002490050138","article-title":"Detergent removal by non-polar polystyrene beads","volume":"27","author":"Rigaud","year":"1998","journal-title":"Eur Biophys J"},{"key":"10.1016\/j.vaccine.2017.10.072_b0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0076-6879(03)67005-9","article-title":"Liposome preparation by detergent removal","volume":"367","author":"Schubert","year":"2003","journal-title":"Methods Enzymol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.072_b0175","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1073\/pnas.0832180100","article-title":"Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles","volume":"100","author":"Hsu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.vaccine.2017.10.072_b0180","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1128\/JVI.02743-07","volume":"82","author":"Lin","year":"2008","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.072_b0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000050047","article-title":"Dendritic cells and chronic hepatitis virus carriers","volume":"44","author":"Akbar","year":"2001","journal-title":"Intervirology"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.072_b0190","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2567.2007.02577.x","article-title":"Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection","volume":"121","author":"Della Bella","year":"2007","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.072_b0195","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2893.2006.00814.x","article-title":"Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection","volume":"14","author":"Miyatake","year":"2007","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.072_b0200","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1189\/jlb.0507268","article-title":"HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production","volume":"82","author":"Waggoner","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.072_b0205","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/jhep.2001.21162","article-title":"Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection","volume":"33","author":"Chang","year":"2001","journal-title":"Hepatology"},{"issue":"5645","key":"10.1016\/j.vaccine.2017.10.072_b0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.1088774","article-title":"HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.10.072_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00130-17","article-title":"Broadening CD4+ and CD8+ T cell responses against hepatitis C virus by vaccination with NS3 overlapping peptide panels in cross-priming liposomes","author":"Filskov","year":"2017","journal-title":"J Virol"},{"issue":"36","key":"10.1016\/j.vaccine.2017.10.072_b0220","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1016\/j.vaccine.2008.06.099","article-title":"c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection","volume":"26","author":"Ogunniyi","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.072_b0225","doi-asserted-by":"crossref","first-page":"e0005300","DOI":"10.1371\/journal.pntd.0005300","article-title":"Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi","volume":"11","author":"Matos","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2017.10.072_b0230","doi-asserted-by":"crossref","first-page":"e110150","DOI":"10.1371\/journal.pone.0110150","article-title":"Cyclic GMP-AMP displays mucosal adjuvant activity in mice","volume":"9","author":"Skrnjug","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.072_b0235","doi-asserted-by":"crossref","first-page":"e104824","DOI":"10.1371\/journal.pone.0104824","article-title":"Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge","volume":"9","author":"Sanchez","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.072_b0240","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"issue":"19\u201320","key":"10.1016\/j.vaccine.2017.10.072_b0245","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/S0264-410X(02)00155-X","article-title":"A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants","volume":"20","author":"Fujihashi","year":"2002","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.10.072_b0250","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0264-410X(01)00292-4","article-title":"Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization","volume":"20","author":"Glueck","year":"2001","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.072_b0255","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4049\/jimmunol.1301812","article-title":"MPYS\/STING-mediated TNF-alpha, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo","volume":"192","author":"Blaauboer","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.10.072_b0260","doi-asserted-by":"crossref","DOI":"10.1096\/fj.201601093R","article-title":"Cyclic dinucleotides modulate induced type I IFN responses in innate immune cells by degradation of STING","author":"Rueckert","year":"2017","journal-title":"FASEB J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T08:00:38Z","timestamp":1535270438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17314809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":52,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17314809"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}